Ovarian Hyperstimulation Syndrome Clinical Trial
Official title:
Clinical Study of Recombinant Human Follitropin for Injection Assisted in Controlled Ovarian Hyperstimulation Assisted IVF-ET
The aim of this study was to evaluate the efficacy and safety of domestic recombinant human follicle stimulating hormone (rhFSH) stimulating ovarian to promote follicular development before assisted reproductive technology, which was non-inferiority than that of the imported rhFSH.
Status | Not yet recruiting |
Enrollment | 252 |
Est. completion date | May 2018 |
Est. primary completion date | December 2017 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 20 Years to 39 Years |
Eligibility |
Inclusion Criteria: - Age is more than 20 years old and less than 39 years old, married. - Applicable for ART controlled ovarian hyperstimulation, such as IVF/ET, ICSI, GIFT, ZIFT and so on. - Regular menstrual cycle (25-35 days). - 18kg/m2=BMI<30kg/m2. - The level of basic serum FSH <10IU / L in the 2nd-5th days of the menstrual cycle, the luteinizing hormone, estradiol and progesterone levels were normal. - The screening period or recent three months of vaginal ultrasound examination showed that the shape of bilateral ovarian and uterine size were normal and 5 = number of basal antral follicle in unilateral ovarian <10, and follicular diameter <10 mm. - The in vitro fertilization and embryo transfer (IVF/ET) and (or) intracytoplasmic sperm injection (ICSI) technology were less than three times used prior to the reproductive treatment (provide copies of previous cases). - Volunteer to participate and sign informed consent. Exclusion Criteria: - There are high risk of ovarian hyperstimulation syndrome (OHSS), such as the subject who has high response to gonadotropin in the previous ovarian hyperstimulation cycle, polycystic ovary syndrome (PCOS), the subject who has severe OHSS cancellation cycle. - Affect the outcome of pregnancy-related diseases (any one): untreated hydrosalpinx, untreated uterine polyps, untreated uterine infection, stage ? ~ IV endometriosis, ovarian cyst> 4cm , uterine fibroids diameter> 4cm, pelvic benign tumor> 4cm, pituitary tumors and malignant tumors of tissues and organs. - The subject has abnormal uterine bleeding. - Affect pregnancy-related endocrine and metabolic diseases (any one): hyperprolactinemia, thyroid disease (including hyperthyroidism, hypothyroidism), hyperandrogenism, adrenal dysfunction (including adrenal hyperfunction, adrenal cortical dysfunction). - The subject has severe liver and kidney dysfunction, which the levels of serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are 2.5 times higher than the upper limit of normal value, and serum creatinine (Cr) and urea nitrogen (BUN) are 2 times higher than the upper limit of normal value. - Severe heart disease, unstable angina pectoris, heart failure grade ? above, acute myocardial infarction and/or old myocardial infarction, hypertension diagnosed according to the 2010 edition of the Chinese Hypertension Prevention Guidelines. - The subject who have contraindications or allergic history for gonadotropin-releasing hormone agonists (GnRH-a), rFSH/human menopausal gonadotropin (hMG), human chorionic gonadotropin (hCG), progesterone drugs. - Positive HIV or syphilis. - The subject has alcoholism, smoking, drug abuse, bad drug abuse habits. - At least one of the spouses has received sperm donor or egg donor or PGD (genetic diagnosis before embryo transfer) and PGS (Preimplantation of embryos before genetic screening)? - The subject received clomiphene or gonadotropin therapy within 1 month before screening? - The subject was participated in last three months or are participating in other clinical research? - Patients with positive serum pregnancy test. - The investigators considered the subject inappropriate to be enrolled in this study. |
Country | Name | City | State |
---|---|---|---|
China | Peking University Third Hospital | Beijing | |
China | Xiangya Hospital Central South University | Changsha | Hunan |
China | Sun Yat-sen Memorial Hospital | Guangzhou | Guangdong |
China | The Sixth Affiliated Hospital of Sun Yat-sen University | Guangzhou | Guangdong |
China | Women's Hospital School of Medicine Zhejiang University | Hangzhou | Zhejiang |
China | The first Affiliated Hospital of Anhui Medical University | Hefei | Anhui |
China | Jiangsu Province Hospital | Nanjing |
Lead Sponsor | Collaborator |
---|---|
GeneScience Pharmaceuticals Co., Ltd. | Peking University Third Hospital, Sixth Affiliated Hospital, Sun Yat-sen University, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, The First Affiliated Hospital of Anhui Medical University, The First Affiliated Hospital with Nanjing Medical University, Women's Hospital School Of Medicine Zhejiang University, Xiangya Hospital of Central South University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The total number of oocytes obtained during the start-up period | Routine ova harvest to determine the number of obtained oocytes | On the days of ovum picking up (hCG trigger 36-38h) | |
Secondary | The number of follicle-1 | The number of follicle with diameter more than 18mm | on the day of hCG day | |
Secondary | The number of follicle-2 | The number of follicle with diameter more than 18mm | on the fifth day of rhFSH ovarian stimulation | |
Secondary | Number of 2PN oocytes | Collected on the day of embryo transfer day after three days of ovum picking up. | ||
Secondary | Number of metaphase II oocytes | Collected on the day of embryo transfer day after three days of ovum picking up, which only collected during ICSI cycle. | ||
Secondary | Number of transferred embryos | Collected on the day of embryo transfer day after three days of ovum picking up. | ||
Secondary | Number of high quality embryos | Collected on the day of embryo transfer day after three days of ovum picking up. | ||
Secondary | Fresh cycle embryo implantation | Collected on the day of embryo transfer day after three days of ovum picking up. | ||
Secondary | rhFSH administered days and vials; administered total dose of rhFSH (IU) | Collected on the day of hCG day. | ||
Secondary | Serum E2 level | Collected on the day of hCG day. | ||
Secondary | High quality embryos rate | Collected on the day of embryo transfer day after three days of ovum picking up. | ||
Secondary | Fertilization rate | Collected on the day of embryo transfer day after three days of ovum picking up. | ||
Secondary | Fresh cycle embryo implantation rate | Collected between 28-35 days after embryo transfer. | ||
Secondary | Biochemical pregnancy rate | Collected between 14-16 days after embryo transfer. | ||
Secondary | Clinical pregnancy rate | Collected between 28-35 days after embryo transfer. | ||
Secondary | Continuous pregnancy rate | Collected after 12 weeks of embryo transfer. | ||
Secondary | The number of follicle-3 | The number of follicle with diameter between 14mm and 18mm. | on the day of hCG day | |
Secondary | The number of follicle-4 | The number of follicle with diameter less than 14mm | on the day of hCG day | |
Secondary | Endometrium thickness (mm) | on the day of hCG |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT00617864 -
The Effect of Human Albumin Infusion on VEGF Levels in Women at Risk for Ovarian Hyperstimulation Syndrome
|
N/A | |
Withdrawn |
NCT01979341 -
The Effect of a Dual Trigger on Intracytoplasmic Sperm Injection (ICSI) Reproductive Outcomes
|
N/A | |
Completed |
NCT01427335 -
Calcium for Prevention of Ovarian Hyperstimulation Syndrome
|
Phase 3 | |
Completed |
NCT01014104 -
Administration of Methylprednisolone for Prevention of Ovarian Hyper Stimulation Syndrome
|
Phase 1/Phase 2 | |
Recruiting |
NCT00119925 -
'SPRING'-Study: "Subfertility Guidelines: Patient Related Implementation in the Netherlands Among Gynaecologists"
|
N/A | |
Completed |
NCT06333691 -
Comparative Study Between Calcium Gluconate With Diosmin, Cabergoline and Cabergoline With Diosmin
|
N/A | |
Terminated |
NCT01714648 -
Can GnRH Agonist Trigger Prevent Ovarian Hyperstimulation Syndrome?
|
Phase 4 | |
Completed |
NCT01500863 -
Endometrial Receptivity After GnRH Agonist Triggering
|
Phase 4 | |
Recruiting |
NCT00417144 -
Comparison Between GnRH Agonist and GnRH Antagonist Protocols of Ovarian Stimulation in PCOS Patients
|
Phase 4 | |
Completed |
NCT03876145 -
The Four Methods of Ovarian Stimulation in Patients With Polycystic Ovarian Syndrome
|
N/A | |
Completed |
NCT05588635 -
Association Between Live Birth Rate and Serum Progesterone During Hormonal Replacement Therapy
|
||
Not yet recruiting |
NCT02392520 -
Luteal Antagonist Versus Conventional Treatment in Women With Severe Early Ovarian Hyperstimulation Syndrome (OHSS)
|
N/A | |
Completed |
NCT00665041 -
Tolerability of Quinagolide in a Dose-titration Regimen in Oocyte Donors at Risk of Developing Ovarian Hyperstimulation Syndrome
|
Phase 2 | |
Completed |
NCT00835523 -
Ovarian Hyperstimulation Syndrome (OHSS) Prevention With Agonist
|
N/A | |
Active, not recruiting |
NCT05638529 -
Dual Trigger" in IVF Patients at High Risk of Ovarian Hyper Stimulation Syndrome
|
Phase 4 | |
Recruiting |
NCT02084940 -
Long Acting GnRH Antagonist in PCOS Women Undergoing IVF
|
N/A | |
Completed |
NCT01815138 -
Co-administration of Low Dose hCG at the Time of GnRH Agonist Trigger or 35 Hours Later for the Prevention of OHSS
|
Phase 4 | |
Completed |
NCT00867659 -
The Role of Cetrotide Acetate in Prevention of Ovarian Hyperstimulation Syndrome (OHSS) in Oocyte Donors
|
N/A | |
Completed |
NCT01569256 -
Ovarian Hyperstimulation Syndrome and Cabergoline
|
N/A | |
Not yet recruiting |
NCT05198128 -
Ovarian Hyperstimulation Syndrome Using Calcium Infusion
|
N/A |